Why the Mesoblast limited share price has been crushed today

The Mesoblast limited (ASX:MSB) share price has been one of the worst performers on the market today. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unfortunately for its shareholders, the Mesoblast limited (ASX: MSB) share price has had a terrible start to the week.

In morning trade the regenerative medicine company's shares fell as much as 11.2% to $2.12 before recovering slightly.

The reason for today's decline was the news that Mesoblast has successfully completed a fully underwritten institutional placement of 26.25 million new shares to raise approximately US$40 million.

The placement price of $2.00 per share represents a significant 16% discount to the last close price.

According to the release the proceeds will be used for the company's ongoing Phase 3 clinical programs, as well as for manufacturing requirements related to product commercialisation.

Despite today's decline, Mesoblast's share price has still rallied an astonishing 53% so far in 2017.

The catalyst for this rally was news that its drug for acute Graft Versus Host Disease (aGVHD) has been awarded "fast track" designation status by the U.S. Food and Drug Administration (FDA).

Fast track designation can shorten the FDA review process by as much as 10 months, potentially saving the company large sums of money and speeding up the commercialisation of the drug.

Its application for fast track status was supported by data from 241 paediatric patients already treated with its aGVHD drug. The next target for the company will be to attain conditional FDA approval for the drug.

Should you buy the dip?

With things looking reasonably bright for the company at long last, I can see why investors might be tempted to buy the dip in its share price today.

But there is still a lot of work to be done and a lot of money to be spent until the company will see sales of the drug hit its top line. In light of this I would suggest investors hold off an investment at this stage, at least until its phase 3 trials have been completed.

In the meantime I feel investors would be better served with an investment in CSL Limited (ASX: CSL) or Mayne Pharma Group Ltd (ASX: MYX).

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »